Moderna mRNA RSV Trial Finds Absolute Risk Reduction <1%
By Peter A. McCullough, MD, MPH Rare illnesses which are mild should not be the target for mass vaccination. Because so few people get the problem, and in the case of respiratory syncytial virus, the illness is so mild and easily treatable with albuterol and budesonide nebulizers, it is hard to make the case for […]
Discuss on Nostr!
Nostr Note ID note1smaq7k363acwxtlk6xkdk3tndfcmleu264pkj9h9l07093fad3hqrvmv5w Open on Primal.net Open on Snort.social Open on Iris.to Open on Coracle.social
New to Nostr?
Create an account now & join the conversation!
Promote it on DissentWatch!
- To advertise this post for $0.02 per visit send bitcoins to the address below
- The post will be promoted daily via social media & our "Featured News" display in multiple places
- You can add more anytime
- Ranking order in the Featured News box is based on the balance remaining
Received: 0 mBTC (0.00 USD)
Spent: 0 mBTC (0.00 USD)
Balance: 0 mBTC (0.00 USD)
The amounts above may be lagging behind. If you just sent a payment click below to get more up to date results and push the post to the "Featured News" box faster.